Inactive

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 and 13.1 as supplemented with additional information in this notice. Quotes are being r... This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 and 13.1 as supplemented with additional information in this notice. Quotes are being requested and this announcement constitutes the only solicitation. The Government contemplates issuing a firm fixed-price purchase order resulting from this solicitation. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2021-04 dated January 19, 2021. The associated North American Industrial Classification System (NAICS) code for this procurement is 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), with an associated size standard of 1,000 employees. In order to assist with onsite testing of FDA regulated products, the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM) requires a study to convert FDA DNA signatures/(FDA PCR assays) onto a biosensor assay. The assay will allow for rapid, sensitive, specific, and affordable verification of FDA regulated products. The contractor will be responsible for the modification and conversion of the FDA assays onto a biosensor. The use of the biosensor should exhibit similar performance (sensitivity and specificity) of the existing validated PCR methods for the detection of FDA DNA regulatory targets. The field-operable nano-biosensors will support CVM on several ongoing projects including analyzing regulatory samples. Please see the RFQ attachment for details.